Market cap
$1,680 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
11.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-10.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-11.1
-
Face value
--
-
Shares outstanding
28,960,580
7 Years Aggregate
CFO
$-364.89 Mln
EBITDA
$-434.52 Mln
Net Profit
$-428.04 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
RAPT Therapeutics (RAPT)
| 71.3 | 0.6 | 68.3 | 541.6 | -38.3 | -15.6 | -- |
|
BSE Sensex*
| -10.1 | -3.6 | 2.5 | -5.7 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
RAPT Therapeutics (RAPT)
| 168.0 | -93.5 | 25.5 | -46.1 | 86.0 | -28.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
RAPT Therapeutics (RAPT)
|
58.0 | 1,680.3 | 0.0 | -105.6 | -- | -64.1 | -- | 11.1 |
| 14.0 | 1,004.5 | 1.5 | -106.6 | -7,919.7 | -50.4 | -- | 5.2 |
Shareholding Pattern
View DetailsAbout RAPT Therapeutics (RAPT)
RAPT Therapeutics, Inc. operates as a clinical-stage immunology-based biopharmaceutical company that focuses on the discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and... inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California. RAPT Therapeutics, Inc. is a subsidiary of Bristol-Myers Squibb Company. Read more
-
CEO, President & Director
Dr. Brian Russell Wong M.D., Ph.D.
-
CEO, President & Director
Dr. Brian Russell Wong M.D., Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for RAPT Therapeutics (RAPT)
What is the current share price of RAPT Therapeutics Inc (RAPT) Today?
The share price of RAPT Therapeutics Inc (RAPT) is $58.01 (NASDAQ) as of 06-Mar-2026 09:30 EDT. RAPT Therapeutics Inc (RAPT) has given a return of -38.25% in the last 3 years.
What is the current PB & PE ratio of RAPT Therapeutics Inc (RAPT)?
Since, TTM earnings of RAPT Therapeutics Inc (RAPT) is negative, P/E ratio is not available.
The P/B ratio of RAPT Therapeutics Inc (RAPT) is 11.05 times as on 06-Mar-2026, a 107 premium to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2024 |
-0.07 |
0.05 |
2023 |
-1.02 |
0.81 |
2022 |
-1.08 |
0.36 |
2021 |
-1.99 |
0.73 |
2020 |
-1.15 |
0.58 |
What is the 52 Week High and Low of RAPT Therapeutics Inc (RAPT)?
The 52-week high and low of RAPT Therapeutics Inc (RAPT) are Rs 58.02 and Rs 5.67 as of 07-Sep-2026.
What is the market cap of RAPT Therapeutics Inc (RAPT)?
RAPT Therapeutics Inc (RAPT) has a market capitalisation of $ 1,680 Mln as on 06-Mar-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in RAPT Therapeutics Inc (RAPT)?
Before investing in RAPT Therapeutics Inc (RAPT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.